-
2024-516052-17-01
10
Patients with a diagnosis of IgAV according to Chapel Hill Consensus C
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2024-517099-39-00
4
2024-11-18
Newly diagnosed transplant ineligible multiple myeloma
-
2024-517004-11-00
5
2024-10-22
Chronic pulmonary aspergillosis
-
2022-501980-42-00
5
2023-12-21
Anemia associated with Chronic Kidney Disease
-
2022-501893-21-00
4
2022-05-03
Acute myocardial infarction
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-516242-19-00
5
2024-11-05
lupus nephritis
-
2023-508614-41-00
4
2024-10-15
The study will be proposed to all adult patients receiving an allogene
-
2023-504986-22-00
5
2024-09-30
surgical antibiotic prophylaxis
-
2023-506590-35-00
4
2024-06-13
Large-Cell NeuroEndocrine
Carcinoma of the lung
-
2023-504127-90-00
5
2024-04-08
Hunter Syndrome and Cognitive Impairment
-
2022-501957-35-00
5
2023-12-12
Generalized periodontitis (stage III or IV and grade A, B or C)
-
2024-515146-16-00
5
2023-05-15
Colorectal surgery
-
2024-513873-36-00
4
2022-02-28
Nervous System Diseases
-
2023-504166-37-00
4
2022-02-01
Advanced ovarian, tubal or peritoneal cancer.
-
2024-511001-28-00
4
2021-12-13
Neuroendocrine tumor
-
2024-514843-27-00
6
2021-10-11
Severe asthma
-
2024-517215-67-00
5
2021-06-11
Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elder
-
2024-513248-27-00
5
2020-07-20
Patients, men or women over 18 old, with inoperable vertebral bone met
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2024-514603-34-00
5
2020-03-02
intermediate-risk differentiated thyroid cancer patients
-
2024-516421-30-00
4
2020-02-05
Neonatal hypoxic-ischaemic encephalopathy
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th